List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 47 studies with search of: "Immunotoxins"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Active, not recruiting BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Drug: BL22 immunotoxin;   Procedure: antibody-drug conjugate therapy;   Procedure: immunotoxin therapy
2 Withdrawn BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Leukemia;   Lymphoma
Interventions: Drug: BL22 immunotoxin;   Procedure: antibody therapy;   Procedure: biological response modifier therapy;   Procedure: immunotoxin therapy
3 Recruiting Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease
Condition: Leukemia
Interventions: Drug: Immunotoxin therapy;   Drug: CAT-8015 immunotoxin;   Procedure: Biological therapy
4 Suspended BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Drug: BL22 immunotoxin;   Procedure: antibody-drug conjugate therapy;   Procedure: immunotoxin therapy;   Procedure: monoclonal antibody therapy
5 Recruiting Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
Conditions: Leukemia;   Hairy Cell Leukemia;   HCL
Interventions: Drug: Immunotoxin therapy;   Drug: CAT-8015 Immunotoxin;   Procedure: Biological therapy
6 Recruiting Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia
Condition: Leukemia
Intervention: Biological: deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins
7 Completed Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia
Condition: Leukemia
Intervention: Biological: BL22 immunotoxin
8 Completed Immunotoxin in Treating Patients With Leukemia or Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Biological: LMB-2 immunotoxin
9 Completed LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
Conditions: Bladder Cancer;   Breast Cancer;   Colorectal Cancer;   Esophageal Cancer;   Gastric Cancer;   Lung Cancer;   Pancreatic Cancer
Intervention: Biological: LMB-9 immunotoxin
10 Completed Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
Conditions: Cervical Cancer;   Fallopian Tube Cancer;   Head and Neck Cancer;   Lung Cancer;   Malignant Mesothelioma;   Ovarian Cancer;   Pancreatic Cancer;   Peritoneal Cavity Cancer
Intervention: Biological: SS1(dsFv)-PE38 immunotoxin
11 Completed Immunotoxin Therapy in Treating Patients With Advanced Cancer
Conditions: Cervical Cancer;   Fallopian Tube Cancer;   Head and Neck Cancer;   Lung Cancer;   Malignant Mesothelioma;   Ovarian Cancer;   Pancreatic Cancer;   Peritoneal Cavity Cancer
Intervention: Biological: SS1(dsFv)-PE38 immunotoxin
12 Recruiting LMB-2 Immunotoxin in Treating Patients With Recurrent or Refractory Hairy Cell Leukemia
Condition: Leukemia
Interventions: Biological: LMB-2 immunotoxin;   Other: pharmacological study
13 Recruiting LMB-2 Immunotoxin in Treating Patients With Cutaneous T-Cell Lymphoma
Condition: Lymphoma
Intervention: Biological: LMB-2 immunotoxin
14 Recruiting LMB-2 Immunotoxin in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
Condition: Leukemia
Intervention: Biological: LMB-2 immunotoxin
15 Active, not recruiting LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
Condition: Metastatic Cancer
Intervention: Biological: LMB-7 immunotoxin
16 Completed Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: LMB-2 immunotoxin;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Other: pharmacological study
17 Completed LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-Small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer
Conditions: Bladder Cancer;   Breast Cancer;   Colorectal Cancer;   Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer
Intervention: Biological: LMB-9 immunotoxin
18 Withdrawn Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease
Condition: Acute Graft Versus Host Disease
Intervention: Biological: IT-Combination
19 Terminated Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
Condition: Neoplasms
Intervention: Drug: SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin
20 Recruiting Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease
Conditions: Leukemia;   Non-Hodgkin's Lymphoma;   NHL
Interventions: Drug: Immunotoxin therapy;   Drug: CAT-8015 Immunotoxin;   Procedure: Biological therapy;   Procedure: Antibody Therapy;   Procedure: Monoclonal Antibody Therapy

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services